Trio

Calmodulin-dependent protein kinases (CaMKs) form a Ca²⁺/calmodulin-responsive signaling network that converts intracellular calcium fluctuations into phosphorylation-dependent cellular responses^[1]. Within the classical CaMKK-CaMKI-CaMKIV kinase cascade, Ca²⁺/calmodulin-dependent protein kinase kinase (CaMKK) phosphorylates and activates CaMKI and CaMKIV, thereby regulating downstream transcriptional programs and diverse Ca²⁺-dependent biological processes^[1][2][3]. Mechanistically, this pathway functions as a core calcium-signaling module that links calcium elevation to neuronal, metabolic, and pathophysiological pathways through activation of specific downstream kinases^[4][5]. In disease-related and experimental models, dysregulated CaMKK signaling has been associated with metabolic disorders, including non-alcoholic fatty liver disease, and pharmacological inhibition of CaMKK2 has shown protective effects in vivo^[6]. Compared with related multifunctional CaMK isoforms, CaMKI and CaMKIV act primarily as direct downstream effectors of CaMKK, whereas CaMKK occupies the upstream regulatory position that controls activation of the kinase cascade^[1][2]. For experimental applications, the small-molecule inhibitor STO-609 has been widely used as a selective CaMKK inhibitor, and structural studies of CaMKKβ-STO-609 complexes have provided a framework for mechanistic analysis and inhibitor development^[6][7]. In addition, TIM-063 was developed as a pan-CaMKK inhibitor that suppresses CaMKI-, CaMKIV-, and AMPK-associated signaling, providing a useful molecular probe for investigating CaMKK-mediated cellular responses^[4].